Forte Biosciences, Inc. (FBRX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$58.2M
Cash & Equivalents
$18.8M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$440M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (3)

NCT #TitlePhaseStatusEnrollment
NCT06982963 Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease PHASE2 Recruiting 100
NCT07205159 A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. PHASE1 Recruiting 32
NCT06905873 A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo PHASE1 Recruiting 64

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for FBRX.

SEC EDGAR Filings

All SEC filings for Forte Biosciences, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.